The abstract is read at the publisher; the summary is JClub's.
PADI1 and PADI3 expression is linked to worse prognosis in KRAS-mutant colorectal and pancreatic cancers, and PADI-dependent mitochondrial adaptation sustains resistance to KRAS inhibitors.
- Why it matters: Even with KRAS(ON) and KRAS(OFF) inhibitors, resistant KRAS-driven tumors limit durable responses, and the mechanisms supporting survival under KRAS blockade remain unclear.
- What they did: The study mapped KRAS-driven enhancer control of PADI1/3, tested KRAS inhibition in sensitive versus resistant cancer models, and used PADIs pharmacological inhibition plus integrated transcriptomic/proteomic profiling to implicate HSPA9/Mortalin.
- The result: PADIs inhibition synergized with KRAS inhibitors, restored sensitivity in resistant cells, and in vivo enhanced antitumor activity; PADI3-driven citrullination of Mortalin supports ATP/ADP cycling, while disrupting this circuitry triggers mitochondrial dysfunction and non-lytic apoptosis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.